Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation.
Rodrigo Martino BofarullGarcía-Cadenas IreneAlbert EsquirolPublished in: Bone marrow transplantation (2021)